Cargando…
TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our pr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721281/ https://www.ncbi.nlm.nih.gov/pubmed/34988114 http://dx.doi.org/10.3389/fmolb.2021.756599 |
_version_ | 1784625305334317056 |
---|---|
author | Nai, Yaru Du, Li Shen, Meiying Li, Tingting Huang, Jingjing Han, Xiaojian Luo, Feiyang Wang, Wang Pang, Da Jin, Aishun |
author_facet | Nai, Yaru Du, Li Shen, Meiying Li, Tingting Huang, Jingjing Han, Xiaojian Luo, Feiyang Wang, Wang Pang, Da Jin, Aishun |
author_sort | Nai, Yaru |
collection | PubMed |
description | Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our previously identified TRAIL-R1–targeting monoclonal antibody (TR1(419)) with antitumor efficacy and produced the TR1(419) chimeric antigen receptor (CAR) T cells. We characterized the phenotypes and functions of these CAR-T cells and found that the third-generation TR1(419)-28BBζ CAR-T cells exhibited greater target sensitivity and proliferative capability, with slightly higher PD-1 expression after antigen stimulation. Importantly, we found that the TR1(419) CAR-T cells could induce TRAIL-R1–positive tumor cell death via a dual mechanism of the death receptor–dependent apoptosis as well as the T-cell–mediated cytotoxicity. Altogether, the TR1(419) CAR-T cells could serve as a promising strategy for targeting the TRAIL-R1–positive tumors. |
format | Online Article Text |
id | pubmed-8721281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87212812022-01-04 TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy Nai, Yaru Du, Li Shen, Meiying Li, Tingting Huang, Jingjing Han, Xiaojian Luo, Feiyang Wang, Wang Pang, Da Jin, Aishun Front Mol Biosci Molecular Biosciences Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our previously identified TRAIL-R1–targeting monoclonal antibody (TR1(419)) with antitumor efficacy and produced the TR1(419) chimeric antigen receptor (CAR) T cells. We characterized the phenotypes and functions of these CAR-T cells and found that the third-generation TR1(419)-28BBζ CAR-T cells exhibited greater target sensitivity and proliferative capability, with slightly higher PD-1 expression after antigen stimulation. Importantly, we found that the TR1(419) CAR-T cells could induce TRAIL-R1–positive tumor cell death via a dual mechanism of the death receptor–dependent apoptosis as well as the T-cell–mediated cytotoxicity. Altogether, the TR1(419) CAR-T cells could serve as a promising strategy for targeting the TRAIL-R1–positive tumors. Frontiers Media S.A. 2021-12-20 /pmc/articles/PMC8721281/ /pubmed/34988114 http://dx.doi.org/10.3389/fmolb.2021.756599 Text en Copyright © 2021 Nai, Du, Shen, Li, Huang, Han, Luo, Wang, Pang and Jin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Nai, Yaru Du, Li Shen, Meiying Li, Tingting Huang, Jingjing Han, Xiaojian Luo, Feiyang Wang, Wang Pang, Da Jin, Aishun TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title | TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title_full | TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title_fullStr | TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title_full_unstemmed | TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title_short | TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy |
title_sort | trail-r1-targeted car-t cells exhibit dual antitumor efficacy |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721281/ https://www.ncbi.nlm.nih.gov/pubmed/34988114 http://dx.doi.org/10.3389/fmolb.2021.756599 |
work_keys_str_mv | AT naiyaru trailr1targetedcartcellsexhibitdualantitumorefficacy AT duli trailr1targetedcartcellsexhibitdualantitumorefficacy AT shenmeiying trailr1targetedcartcellsexhibitdualantitumorefficacy AT litingting trailr1targetedcartcellsexhibitdualantitumorefficacy AT huangjingjing trailr1targetedcartcellsexhibitdualantitumorefficacy AT hanxiaojian trailr1targetedcartcellsexhibitdualantitumorefficacy AT luofeiyang trailr1targetedcartcellsexhibitdualantitumorefficacy AT wangwang trailr1targetedcartcellsexhibitdualantitumorefficacy AT pangda trailr1targetedcartcellsexhibitdualantitumorefficacy AT jinaishun trailr1targetedcartcellsexhibitdualantitumorefficacy |